This site contains promotional information intended only for healthcare professionals resident in Great Britain

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutConjugate TechnologyPneumococcal DiseaseDosing & AdministrationDosing & AdministrationDosing, Administration & StoragePrevious Pneumococcal VxClinical Trial ProgrammeClinical Evidence & SafetyClinical Trial ProgrammeSafety ProfilePrivate Vaccination Service Private Vaccination ServiceIdentifying Those at Increased Risk of Pneumococcal Pneumonia

The content of this site is based on the Prescribing Information for APEXXNAR®▼ (pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)) for Great Britain. The Prescribing Information for Great Britain can be found here. Prescribing Information for Prevenar 13® (pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)) can be found here.

Clinical Trial Programme

The safety profile of APEXXNAR was evaluated in 4,552 participants 18 years of age and older in six clinical trials (two Phase 1, one Phase 2, and three Phase 3 studies)1

Phase 3 studies were conducted in pneumococcal vaccine-naïve and previously vaccinated adults1.

Patients receiving APEXXNAR in Phase 3 trials (safety and immunogenicity) N=4,263
 Safety Profile of APEXXNAR

Information about the safety profile and adverse reactions associated with APEXXNAR1

 

 See the data → Loading

  Key Information on APEXXNAR

Key information about dosing, administration and storage for APEXXNAR1

 

Get the facts →Loading

 Who is at risk?

Watch videos about chronic conditions that can put your patients at increased risk of pneumococcal disease

 Watch now →Loading

References: 

  1. APEXXNAR GB (Pneumococcal polysaccharide conjugate vaccine). Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/13461.
  2. Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, et al. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥ 18 Years. Clin Infect Dis. 2022;75(3):390-8.
  3. Cannon K, Elder C, Young M, Scott DA, Scully IL, Baugher G, et al. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥ 65 years of age with different prior pneumococcal vacccination. Vaccine 2021;39(51):7494-502.
  4. Klein NP, Peyrani P, Yacisin K, Caldwell N, Xu X, Scully IL, et al. A phase 3, randomized double-blind study to evaluate the immunogenicity and saftey of 3 lots of 20-valent pneumococcal vaccine in pneumococcal vaccine naive adults 18 through 49 years of age. Vaccine. 2021;39(38):5428-35.
PP-PNR-GBR-0155. March 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​